

- **Name:** Dong-Wan Kim
  - **Current Position & Affiliation:** Professor, Department of Internal Medicine, Seoul National University Hospital
  - **Country:** Korea
- 

**• Educational Background:**

- 1994 M.D. / Seoul National University, Seoul, Korea
- 2007 Ph.D. / Seoul National University, Seoul, Korea

**• Professional Experience:**

- 1994-1999 Internship and Residency in Internal Medicine  
Seoul National University Hospital
- 1999- 2002 Public Health Doctor  
Korea Food and Drug Administration
- 2002-2003 Clinical Fellow  
Seoul National University Hospital
- 2003-2008 Clinical Professor  
Seoul National University Hospital
- 2007-2008 Research Fellow  
Duke Comprehensive Cancer Center, Durham, NC
- 2008 -2017 Assistant and Associate Professor  
Seoul National University College of Medicine / Hospital
- 2017~Current Professor  
Seoul National University College of Medicine / Hospital

**• Professional Organizations:**

- KSMO, KCA, KALC
- ASCO, AACR, ESMO, IASLC

**• Main Scientific Publications:**

**Kim DW**, Kim HG, Kim JH, et al. Randomized phase III trial of irinotecan plus cisplatin versus etoposide plus cisplatin in chemotherapy-naïve Korean patients with extensive-disease small cell lung cancer. *Cancer Res Treat* 2019;51:119-127.

**Kim DW**, Lee DH, Han JY, et al. Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. *Lung Cancer* 2019;135:66-72.

**Kim DW**, Tiseo M, Ahn MJ, et al. Brigatinib in Patients with Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized,

Multicenter Phase II Trial. *J Clin Oncol* 2017;35:2490-98.

**Kim DW**, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. *Lancet Oncol* 2016; 17:452-63.

Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, **Kim DW**. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. *J Clin Oncol* 2016;34:661-8.

Herbst RS, Baas P, **Kim DW**, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet* 2016;387:1540-50.

Park S, Koh J, **Kim DW** (corresponding), Kim M, Keam B, Kim TM, Jeon YK, Chung DH, Heo DS. MET amplification, protein expression, and mutations in pulmonary adenocarcinoma. *Lung Cancer* 2015;90:381-7.

Kim TM, Song A, **Kim DW** (corresponding), Kim S, Ahn YO, Keam B, Jeon YK, Lee SH, Chung DH, Heo DS. Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor. *J Thorac Oncol* 2015;10:1736-44.

Jänne PA, Yang JC, **Kim DW**, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. *N Engl J Med* 2015;372:1689-99.

Song A, Kim TM, **Kim DW** (corresponding), Kim S, Keam B, Lee SH, Heo DS. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer. *Clin Cancer Res* 2015;21:2379-87.